Stay updated on Pembrolizumab & PLD in Platinum Resistant Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & PLD in Platinum Resistant Ovarian Cancer Clinical Trial page.

Latest updates to the Pembrolizumab & PLD in Platinum Resistant Ovarian Cancer Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedPublications are now described as automatically filled from PubMed and may not all pertain to the study, and the page revision has been updated to v3.3.2.SummaryDifference0.1%

- Check21 days agoChange DetectedThe banner about government funding status and operating status has been removed from the page.SummaryDifference0.4%

- Check35 days agoChange DetectedNo significant additions or deletions were detected; the Study Details page content appears unchanged, including eligibility criteria and locations.SummaryDifference0.4%

- Check64 days agoChange DetectedUpdate includes a prominent operating-status notice and a version upgrade from v3.1.0 to v3.2.0. The core effect is informing users about possible delays and the current open status of the NIH Clinical Center.SummaryDifference3%

- Check71 days agoChange Detected- Added a new version tag (v3.1.0). - Removed a specific resource (Ovarian cancer) and an older revision tag (v3.0.2).SummaryDifference0.3%

- Check85 days agoChange DetectedUpdated revision from v3.0.1 to v3.0.2. Removed the 'Back to Top' element; no changes to core content, pricing, stock, or time slots.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab & PLD in Platinum Resistant Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & PLD in Platinum Resistant Ovarian Cancer Clinical Trial page.